WE
MRNA icon

Wealth Effects’s Moderna MRNA Stock Holding History

Wealth Effects’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,106
Closed -$218K – 234
2023
Q3 		$218K Sell
2,106
-285
-12% -$31.8K 0.11% 158
2023
Q2 		$291K Hold
2,391
– – 0.13% 137
2023
Q1 		$367K Buy
2,391
+20
+0.8% +$3.3K 0.19% 122
2022
Q4 		$426K Hold
2,371
– – 0.24% 98
2022
Q3 		$280K Hold
2,371
– – 0.17% 124
2022
Q2 		$339K Buy
2,371
+300
+14% +$42.9K 0.2% 109
2022
Q1 		$357K Sell
2,071
-250
-11% -$42.1K 0.17% 124
2021
Q4 		$589K Buy
+2,321
New +$679K 0.24% 85

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealth Effects's MRNA Position: Q4 2023 in Review

Wealth Effects sold out of Moderna (MRNA) in Q4 2023, closing a stake of 2,106 shares — an estimated $218K sold.

Wealth Effects first reported a position in MRNA in Q4 2021 and held it in 8 quarters. The position peaked at $589K in Q4 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Wealth Effects reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Wealth Effects sold 2,106 Moderna shares in Q4 2023, an estimated $218K.
  • Wealth Effects first reported a position in Moderna in Q4 2021 and held it in 8 quarters.
  • Wealth Effects's Moderna position peaked at $589K in Q4 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Wealth Effects's 13F filing for Q4 2023, filed 29 Jan 2024.